Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Alzheimer Disease Clinical Trial

Official title:

Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00018278
• Other study ID #: AGCG-004-98S
• Status: Completed
• Phase: Phase 4
• First received: July 3, 2001
• Last updated: January 20, 2009
• Start date: October 1998
• Est. completion date: September 2001

Study information

• Verified date: December 2004
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: September 2001
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 55 Years to 85 Years

Eligibility

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Aricept

• Exelon

• Nicoderm Patch

Locations

Country	Name	City	State
United States	Department of Veterans Affairs	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States,